Effects of Smoking on Haloperidol and Reduced Haloperidol Plasma Concentrations and Haloperidol Clearance

Overview

Journal Psychopharmacology (Berl)

Specialty Pharmacology

Date 1986 Jan 1

PMID 3101102

Citations 18

Authors

M W Jann

S R Saklad

L Ereshefsky

A L Richards

C A Harrington

C M Davis

Affiliations

Soon will be listed here.

Abstract

Plasma concentrations of haloperidol and its reduced metabolite (reduced haloperidol) were investigated in cigarette smokers (N = 23) and nonsmokers (N = 27). Steady-state plasma concentrations were obtained 12 h post bedtime dose. Haloperidol and reduced haloperidol concentrations were determined by RIA. Reduced haloperidol was separated by selective succinylation and liquid chromatography. Patients were clinically assessed with the Clinical Global Impression Scale (CGIS). Smokers had significantly lower haloperidol and reduced haloperidol plasma concentrations than nonsmokers (P less than 0.01, P less than 0.05). Clearance of haloperidol was significantly greater in smokers compared to nonsmokers (P = 0.0052). CGIS assessments did not show significant differences between smokers and nonsmokers. Plasma concentrations should be carefully monitored when patients either start or stop smoking.

Citing Articles

Pairwise genetic meta-analyses between schizophrenia and substance dependence phenotypes reveals novel association signals with pharmacological significance.

Greco L, Reay W, Dayas C, Cairns M Transl Psychiatry. 2022; 12(1):403.

PMID: 36151087 PMC: 9508072. DOI: 10.1038/s41398-022-02186-4.

Transgenerational evidence of increases in dopamine D2 receptor sensitivity in rodents: Impact on sensorimotor gating, the behavioral response to nicotine and BDNF.

Drew Gill W, Burgess K, Vied C, Brown R J Psychopharmacol. 2021; 35(10):1188-1203.

PMID: 34291671 PMC: 9169618. DOI: 10.1177/02698811211033927.

Effects of an adenosine A agonist on the rewarding associative properties of nicotine and neural plasticity in a rodent model of schizophrenia.

Drew Gill W, Shelton H, Burgess K, Brown R J Psychopharmacol. 2019; 34(1):137-144.

PMID: 31694445 PMC: 9199013. DOI: 10.1177/0269881119885917.

The effect of nicotine dependence on psychopathology in patients with schizophrenia.

Yee A, Bt Nek Mohamed N, Binti Hashim A, Loh H, Harbajan Singh M, Ng C Biomed Res Int. 2015; 2015:730291.

PMID: 26060820 PMC: 4427765. DOI: 10.1155/2015/730291.

Clinically significant psychotropic drug-drug interactions in the primary care setting.

English B, Dortch M, Ereshefsky L, Jhee S Curr Psychiatry Rep. 2012; 14(4):376-90.

PMID: 22707017 PMC: 4335312. DOI: 10.1007/s11920-012-0284-9.

References

Stimmel G, Falloon I . Chlorpromazine plasma levels, adverse effects, and tobacco smoking: case report. J Clin Psychiatry. 1983; 44(11):420-2. View

Swett Jr C . Drowsiness due to chlorpromazine in relation to cigarette smoking. A report from the Boston Collaborative Drug Surveillance Program. Arch Gen Psychiatry. 1974; 31(2):211-4. DOI: 10.1001/archpsyc.1974.01760140063010. View

Korpi E, Phelps B, Granger H, Chang W, Linnoila M, Meek J . Simultaneous determination of haloperidol and its reduced metabolite in serum and plasma by isocratic liquid chromatography with electrochemical detection. Clin Chem. 1983; 29(4):624-8. View

Perel J, Hurwic M, Kanzler M . Pharmacodynamics of imipramine in depressed patients. Psychopharmacol Bull. 1975; 11(4):16-8. View

Kirch D, BIGELOW L, Wyatt R . The interpretation of plasma haloperidol concentrations. Arch Gen Psychiatry. 1985; 42(8):838-40. DOI: 10.1001/archpsyc.1985.01790310106016. View

Holley F, Magliozzi J, Stanski D, LOMBROZO L, Hollister L . Haloperidol kinetics after oral and intravenous doses. Clin Pharmacol Ther. 1983; 33(4):477-84. DOI: 10.1038/clpt.1983.65. View

Linnoila M, George L, Guthrie S, LEVENTHAL B . Effect of alcohol consumption and cigarette smoking on antidepressant levels of depressed patients. Am J Psychiatry. 1981; 138(6):841-2. DOI: 10.1176/ajp.138.6.841. View

Hollister L, Kim D . Intensive treatment with haloperidol of treatment-resistant chronic schizophrenic patients. Am J Psychiatry. 1982; 139(11):1466-8. DOI: 10.1176/ajp.139.11.1466. View

Ereshefsky L, Davis C, Harrington C, Jann M, Browning J, Saklad S . Haloperidol and reduced haloperidol plasma levels in selected schizophrenic patients. J Clin Psychopharmacol. 1984; 4(3):138-42. View

10.

Vinarova E, Vinar O, Kalvach Z . Smokers need higher doses of neuroleptic drugs. Biol Psychiatry. 1984; 19(8):1265-8. View

11.

Browning J, Harrington C, Davis C . Quantification of reduced haloperidol and haloperidol by radioimmunoassay. J Immunoassay. 1985; 6(1-2):45-66. DOI: 10.1080/01971528508063020. View

12.

Korpi E, Wyatt R . Reduced haloperidol: effects on striatal dopamine metabolism and conversion to haloperidol in the rat. Psychopharmacology (Berl). 1984; 83(1):34-7. DOI: 10.1007/BF00427418. View

13.

Ereshefsky L, Jann M, Saklad S, Davis C, Richards A, BURCH N . Effects of smoking on fluphenazine clearance in psychiatric inpatients. Biol Psychiatry. 1985; 20(3):329-32. DOI: 10.1016/0006-3223(85)90063-0. View

14.

Norman T, Burrows G, Maguire K, Rubinstein G, SCOGGINS B, Davies B . Cigarette smoking and plasma nortriptyline levels. Clin Pharmacol Ther. 1977; 21(4):453-6. DOI: 10.1002/cpt1977214453. View

15.

Miller D, Hershey L, Duffy J, Abernethy D, Greenblatt D . Serum haloperidol concentrations and clinical response in acute psychosis. J Clin Psychopharmacol. 1984; 4(6):305-10. View

16.

PANTUCK E, Pantuck C, Anderson K, Conney A, Kappas A . Cigarette smoking and chlorpromazine disposition and actions. Clin Pharmacol Ther. 1982; 31(4):533-8. DOI: 10.1038/clpt.1982.72. View